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ABSTRACT
Objective Since 2003, over 2000 cases of
lymphogranuloma venereum (LGV) have been diagnosed
in the UK in men who have sex with men (MSM). Most
cases present with proctitis, but there are limited data
on how to differentiate clinically between LGV and other
pathology. We analysed the clinical presentations of
rectal LGV in MSM to identify clinical characteristics
predictive of LGV proctitis and produced a clinical
prediction model.
Design A prospective multicentre case–control study
was conducted at six UK hospitals from 2008 to 2010.
Cases of rectal LGV were compared with controls with
rectal symptoms but without LGV.
Methods Data from 98 LGV cases and 81 controls
were collected from patients and clinicians using
computer-assisted self-interviews and clinical report
forms. Univariate and multivariate logistic regression was
used to compare symptoms and signs. Clinical prediction
models for LGV were compared using receiver operating
curves.
Results Tenesmus, constipation, anal discharge and
weight loss were signiﬁcantly more common in cases
than controls. In multivariate analysis, tenesmus and
constipation alone were suggestive of LGV (OR 2.98,
95% CI 0.99 to 8.98 and 2.87, 95% CI 1.01 to 8.15,
respectively) and that tenesmus alone or in combination
with constipation was a signiﬁcant predictor of LGV
(OR 6.97, 95% CI 2.71 to 17.92). The best clinical
prediction was having one or more of tenesmus,
constipation and exudate on proctoscopy, with a
sensitivity of 77% and speciﬁcity of 65%.
Conclusions This study indicates that tenesmus alone
or in combination with constipation makes a diagnosis




Since 2003, an outbreak of lymphogranuloma
venereum (LGV) has been recognised in Western
Europe affecting men who have sex with men
(MSM)1 with the serovar L2b identiﬁed as the
causative organism.2 By June 2012, 2138 LGV cases
had been diagnosed in the UK with 99% in MSM,
the majority with established HIV infection.3
In this current outbreak, LGV usually presents as
a primary proctitis, sometimes associated with con-
stitutional symptoms.4 Anal discharge and proctitis
are commonly reported,5 6 but there are limited
data on the speciﬁcity of these symptoms and signs,
making it difﬁcult to differentiate clinically
between LGV and other infections. LGV proctitis
may also resemble inﬂammatory bowel disease in
symptoms, endoscopic ﬁndings and histology and
may result in referral to other specialties resulting
in delayed diagnosis and increased risk of complica-
tions.7–11 Relatively few MSM diagnosed with
LGV have presented with the inguinal syndrome12
or perianal ulceration,13 and in the UK no signiﬁ-
cant reservoir of asymptomatic or undiagnosed
infection has been identiﬁed, in contrast to data
from the Netherlands.14–16 The persistence of LGV
in the UK over nearly a decade shows that control
efforts have failed to limit ongoing transmission.
Objectives
We aim to describe in detail the clinical presenta-
tion and course of LGV in MSM, and to identify
clinical symptoms and signs predictive of LGV
compared with other forms of proctitis and to




A prospective multicentre case–control study. This
is part of a wider study (LGV-net) that explored
the clinical, epidemiological and microbiological
characteristics of LGV.17 In the study of risk factors
for LGV acquisition, two control groups were used,
symptomatic and asymptomatic. However, in the
analysis presented here, we are using only the
symptomatic controls as we aim to identify the spe-
ciﬁc symptoms and clinical characteristics distin-
guishing LGV from other presentations.
Setting
Subjects were recruited from Genitourinary
Medicine, HIV and Sexual Health Clinics, based in
six hospitals located in London, Brighton and
Glasgow, selected to include those seeing signiﬁcant
numbers of cases of LGV in the UK. National
ethics committee approval was granted for the
study (07/H0712/156) and individual informed
patient consent obtained.
Participants
Cases were MSM diagnosed with rectal LGV
(included rectal asymptomatic and presymptomatic
patients) between August 2008 and December
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2010 at one of the participating clinics. Controls were selected
(one control per case) by staff involved in the study, from MSM
presenting to the same centre during the same week as the case.
The inclusion criteria for controls were patients presenting with
symptoms of proctitis, anogenital ulceration or inguinal lymph-
adenopathy who tested negative for LGV and who had reported
anogenital sex with a man in the previous 3 months. We aimed
to recruit one symptomatic control for each case from the same
centre, and seen in the same date period as the case. All controls
reported symptoms of proctitis, some also had perianal ulcer-
ation. Ten patients initially recruited as symptomatic controls
and nine asymptomatic controls who were subsequently diag-
nosed with LGV were transferred to the LGV case group and
further controls recruited. Men who were unable to provide
informed consent, who lacked sufﬁcient English or were unable
to complete the computer-assisted self-interviews (CASIs) were
not eligible.
Investigations
Cases and controls were investigated using standard clinic proto-
cols, including testing for chlamydia and gonorrhoea from
rectum, urethra/urine and pharynx by a variety of NAATs. All
samples from cases and controls that tested positive for
Chlamydia trachomatis were sent to the relevant Sexually
Transmitted Bacterial Reference Laboratory (STBRL) in England
or Scotland for LGV testing using an LGV-speciﬁc real-time
PCR assay.18 Proctoscopy was carried out on all those with
rectal symptoms unless there were clinical contraindications,
such as signiﬁcant pain or the patient declined. Serological
testing for HIV, syphilis and hepatitis C was undertaken accord-
ing to clinical need.
Data collection and handling
Patients completed a web-based CASI providing detailed
accounts of sociodemographics, risk behaviour and previous
medical history. A separate web-based clinical report form
(CRF) was completed by the recruiting team, detailing patient
symptoms, relevant past medical and sexual history, examination
ﬁndings and results of investigations. Patients were offered a full
sexual health screen and received standard clinical care. Cases
were followed up by undergoing a test of cure 4 weeks and
6 months after completion of treatment and re-screened for all
sexually transmitted infections (STIs) including HIV, syphilis and
hepatitis C if initially negative. Cases were asked to complete a
further CASI at the test of cure follow-up concerning experi-
ences of LGV symptoms and treatment.
Data from the online CASI and the CRF were linked using a
unique study number; no personal identifying information was
collected. Data were then combined into a standard database
format, cleaned and exported to a statistical package for
analysis.
Main outcome measure and statistical analysis
A preliminary descriptive univariate analysis was carried out
comparing the clinical presentation and ﬁndings for cases and
controls. Continuous variables were initially explored using
t tests. Missing data were omitted. Key symptoms and signs
(p<0.05) predictive of LGV were then analysed further in a
multivariable logic regression model. The ﬁnal multivariable
model presented shows signiﬁcant independent predictors of
LGV adjusted for the residual or confounding effects of other
variables in the model. Using the results of the univariate and
multivariate analysis, we constructed alternative clinical predic-
tion models for LGV in men with rectal symptoms. Symptoms
and signs with the largest ORs were entered into different
models and receiver operating curves plotted of 1-speciﬁcity




In total, 98 rectal LGV cases and 81 symptomatic controls
between August 2008 and December 2010. The recruitment
rate was 84%; 78% for cases and 87% controls.
Descriptive data
Both cases and controls were mainly men in their 30s and 40s,
around half of whom were born in the UK, and the majority of
whom reported previous STIs (table 1). Cases were signiﬁcantly
more likely than controls to be of white ethnicity (90% vs 78%),
to be coinfected with HIV (90% vs 72%) and to have had one or
more previous STIs (99% vs 84%). Controls had a wide range of
eventual diagnoses: 44 had one or more STIs (table 2), several
patients had coinfections, 30 had no speciﬁc diagnosis and 7 had
non-STI diagnoses (3 haemorrhoids, 2 anal ﬁssures, 1 giardia and
1 microsporidiosis). Ten (10%) LGV cases and eight (10%)
symptomatic controls gave a history of hepatitis C. Six LGV cases
had a recently (within 6 months) positive hepatitis C PCR with
no previous history of hepatitis C detected at the follow-up visit
for LGV. Among the nine LGV cases known not to have HIV
infection at baseline, one seroconverted for HIV within the
6-month follow-up.
Some cases had other STIs in addition to rectal LGV (table 2).
LGV was also detected in the pharynx in one patient who pre-
sented with rectal symptoms but no pharyngeal symptoms.
However, screening for pharangeal C trachomatis was not
routine at most of the participating clinics and was carried out
for only 20 cases and 24 controls included in this study.
Although the majority of the cases had rectal symptoms, nine
reported no rectal symptoms at the time of their initial positive
test for C trachomatis. Of these, four were contacts of LGV and
the remainder reported other genital symptoms. One month
after completion of treatment, ﬁve of the nine reported having
developed at least one rectal symptom in the period between
testing and treatment, two reported no symptoms throughout
and two did not complete the follow-up questionnaire where
LGV symptoms were recorded.
Median duration of symptoms was 13 days in cases and
7 days in controls, although eight cases and eight controls
reported being symptomatic for over a month before seeking
care. The most common symptoms in men with LGV were
rectal discharge (66%), bleeding (61%) and anal pain (56%),
followed by tenesmus (33%) and a change in bowel habit, with
around one in three reporting constitutional symptoms
(table 3). Tenesmus, constipation, anal discharge and weight loss
were signiﬁcantly more common in cases than controls. A
similar proportion of cases and controls also reported genital
symptoms (10% and 15%, respectively), mostly dysuria and
urethral discharge.
Proctoscopy was performed on 81 (83%) cases and 73 (90%)
controls (table 3) with cases signiﬁcantly less likely to be
reported as ‘normal’ and more likely to have proctitis, exudate
and bleeding, with exudate and rectal bleeding more signiﬁ-
cantly associated with LGVon univariate analysis.
Multivariable analyses
In a multivariate model combining these symptoms and signs
(adjusting for other variables), tenesmus and constipation alone
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were suggestive of LGV, with an OR of 2.98 (95% CI 0.99 to
8.98) and 2.87 (95% CI 1.01 to 8.15), respectively. Constipation
or tenesmus occurred in approximately half (47%) of LGV cases
in our study. If tenesmus alone, or in combination with constipa-
tion, was present, this was highly suggestive that LGV was the
cause of the rectal symptoms, with an OR of 6.97 (95% CI 2.71
to 17.92). These associations were modiﬁed slightly if rectal gon-
orrhoea was added to the model, with tenesmus becoming of
borderline signiﬁcance (aOR 2.82, 95% CI 0.99, 8.86), constipa-
tion becoming more strongly associated (aOR 3.45, 95% CI 1.19
to 10.04) and gonorrhoea itself being an independent predictor
of LGV (aOR 4.02, 95% CI 1.17 to 13.80).
We assessed potential clinical prediction models using combi-
nations of the following symptoms and signs: tenesmus, consti-
pation, weight loss, exudate and bleeding on proctoscopy, and a
normal proctoscopy. The best balance of sensitivity and speciﬁ-
city was found in an algorithm combining tenesmus, constipa-
tion and exudate on proctoscopy; having at least one of these
symptoms and signs gives a sensitivity of 77% and speciﬁcity of
65% (ﬁgure 1). We did not include gonorrhoea in the model
since this would not be usually known at initial presentation
unless suspected on Gram stain on microscopy.
The treatment regimen was recorded for 95 (97%) of the
cases: the majority (90/95, 95%) received the recommended






N (%) OR (95% CI) p Value
N=98 N=81
Recruitment setting
HIV clinic 65 (66) 55 (68) Ref 0.757*
Genitourinary medicine clinic 27 (28) 23 (28) 0.99 (0.51 to 1.93)
Other† 6 (6) 3 (4) 1.69 (0.40 to 7.08)
Reason attended clinic
Symptoms 75 (78) 72 (89) Ref 0.075*
Routine/check up 12 (12) 3 (4) 3.84 (1.04 to 14.17)
Other‡ 9 (9) 6 (7) 1.44 (0.49 to 4.25)
Age median (IQR) 39.5 (34–46) 37 (30–44) n/a 0.087§
Ethnicity—white (UK or other) 87 (90) 63 (79) 2.35 (1.01 to 5.47) 0.048
Born in UK 54 (56) 53 (65) 0.66 (0.36 to 1.22) 0.186
Known HIV-positive 88 (90) 58 (72) 3.49 (1.55 to 7.87) 0.003
Previous hepatitis C 10 (10) 8 (10) 1.02 (0.38 to 2.73) 0.964
Previous gonorrhoea 67 (68) 43 (54) 1.86 (1.01 to 3.43) 0.047
Previous syphilis 47 (48) 31 (39) 1.46 (0.80 to 2.65 0.219
Previous LGV 16 (16) 8 (10) 1.76 (0.71 to 4.34) 0.223
Previous chlamydia (non-LGV) 51 (52) 30 (38) 1.81 (0.99 to 3.30) 0.054
Any previous sexually transmitted infection 97 (99) 67 (84) 18.82 (2.4 to 147.3) 0.005
HIV postexposure prophylaxis related: one case and two controls. Serological tests for syphilis follow-up: one case. Confirm new HIV: one control.
*p Value for trend.
†MSM or SW dedicated clinics.
‡Contact tracing: six cases and three controls.
§Wilcoxon rank sum test for medians.
LGV, lymphogranuloma venereum; MSM, men who have sex with men; SW, sex worker.





N (%) OR (95% CI) p Value
N=98 N=81
Rectal chlamydia (non-LGV) n/a 20 (25) n/a
Urethral chlamydia 5 (6) 3 (4) 1.43 (0.33 to 6.20) 0.629
Pharyngeal chlamydia* 4 0 n/a
Rectal gonorrhoea 18 (19) 6 (8) 2.81 (1.06 to 7.46) 0.038
Urethral gonorrhoea 3 (3) 2 (3) 1.28 (0.21 to 7.85) 0.791
Pharyngeal gonorrhoea 2 (2) 2 (2) 0.89 (0.12 to 6.44) 0.905
Non-gonococcal urethritis 7 (8) 2 (3) 3.09 (0.62 to 15.32) 0.168
Anogenital herpes 2 (22) 6 (8) 0.26 (0.05 to 1.34) 0.168
Anogenital warts 8 (9) 10 (13) 0.64 (0.24 to 1.71) 0.371
Syphilis (new infection)† 1 (1) 5 (7) 0.17 (0.02 to 1.46) 0.105
*20 cases and 24 controls were screened for pharyngeal chlamydia.
†78 cases and 69 controls had syphilis serology results available.
LGV, lymphogranuloma venereum.
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dose of doxycycline (100 mg twice daily for 3 weeks), 71 of
whom had this as ﬁrst line, the remainder once the diagnosis
was conﬁrmed.
DISCUSSION
Tenesmus, constipation, anal discharge and weight loss were sig-
niﬁcantly more common presenting symptoms in men with
LGV compared with controls. In multivariate analysis, constipa-
tion and tenesmus alone were suggestive of having LGV; men
with tenesmus alone or in combination with constipation were
almost seven times more likely to have LGV. The median dur-
ation for rectal symptoms for LGV cases was 13 days, ranging
from 1 day to a year, similar to that reported elsewhere.19
Proctoscopic ﬁndings helped differentiate cases and controls,
with exudate or bleeding being signiﬁcant predictors of LGV on
univariate analysis.
We developed a simple clinical algorithm to assist in the diag-
nosis of LGV in men with rectal symptoms: having one or more
of tenesmus, constipation and exudate on proctoscopy had a
sensitivity of 77% and speciﬁcity 65%. These parameters are
not high enough to be diagnostic, but may improve initial
assessment, and presumptive treatment while diagnostic results
are awaited. Asymptomatic rectal LGV cases were included in
our analyses to reﬂect clinical practice; however, only 9% (9/98)
of cases had no rectal symptoms at presentation: the majority
were ‘presymptomatic’ and went on to develop symptoms, with
only two remaining persistently asymptomatic.
This differs to the 27% asymptomatic rate observed in the
Netherlands, which may reﬂect LGV testing of all positive rectal
chlamydia specimens irrespective of symptoms (Dr Henry de
Vries, personal communication). UK practice is for type-speciﬁc
testing of chlamydia only in symptomatic patients and
contacts.20
Limitations
Our study is limited by the high number of clinicians examining
patients, and therefore proctoscopic ﬁndings and rectal micros-
copy may not be consistently reported, and not all LGV cases
had proctoscopy. Other studies have suggested that proctitis
detected by proctoscopic examination together with greater
than 10 or 20 poylmorphonuclear leucocytes per high-power
ﬁeld on a rectal smear is suggestive of LGV.5 6
The study is strengthened by the prospective recruitment,
multisite setting and systematic data collection using CASI (par-
ticipants) and online CRFs (clinicians). While these methods do
not eliminate variation in data quality, they will have improved
the validity of reports on symptoms and signs compared with
other studies of LGV that have often been based on retrospect-
ive case note review.
Interpretation
Other studies have reported the association with tenesmus and
constipation.21–25 Our study is the ﬁrst to quantify this





n (%) OR (95% CI) p Value
Total 98 81
Any rectal symptoms 89 (91) 81 (100) n/a
Duration: median days (IQR) 13 (5–21) 7 (3.5–14.5) n/a 0.146*
Anal discharge 65 (66) 36 (44) 2.46 (1.34 to 4.51) 0.004
Rectal bleeding 60 (61) 41 (51) 1.54 (0.85 to 2.79) 0.155
Anal pain 55 (56) 36 (44) 1.60 (0.88 to 2.89) 0.121
Tenesmus 32 (33) 6 (7) 6.06 (2.39 to 15.40) <0.001
Constipation 29 (30) 8 (10) 3.84 (1.64 to 8.96) 0.002
Loose stools/diarrhoea 28 (29) 20 (25) 1.22 (0.63 to 2.38) 0.560
Any constitutional symptoms 33 (34) 21 (26) 1.45 (0.76 to 2.78) 0.265
Malaise 19 (20) 8 (10) 2.19 (0.90 to 5.32) 0.082
Fever 16 (16) 8 (10) 1.78 (0.72 to 4.40) 0.213
Weight loss 11 (11) 1 (1) 10.10 (1.28 to 80.06) 0.029
Any genital or inguinal symptoms 11 (11) 12 (15) 0.73 (0.30 to 1.75) 0.476
Proctoscopy findings† 81 (91) 73 (91)
Normal 8 (10) 16 (22) 0.39 (0.16 to 0.97) 0.044
Proctitis 52 (65) 34 (47) 2.08 (1.08 to 3.98) 0.028
Rectal bleeding 31 (39) 13 (18) 2.87 (1.36 to 6.08) 0.006
Exudate 47 (59) 20 (28) 3.70 (1.87 to 7.32) <0.001
Lesion or/ulcer 13 (16) 10 (14) 1.22 (0.50 to 3.00) 0.661
*Wilcoxon rank sum test for medians.
†Proctoscopy was not performed in 17 cases (9 asymptomatic, 1 unable to be performed because of pain, 2 had perianal lesions only, 1 declined, 4 reason not recorded) and 8 controls
(2 because of pain, 3 perianal lesions, 1 abdominal cramps, 2 reason not recorded).
LGV, lymphogranuloma venereum.
Figure 1 Receiver operator curve for clinical algorithm of tenesmus
(1)+constipation (1)+exudate on proctoscopy (1).
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association that has been postulated as resulting from the trans-
mural and perirectal inﬂammation and oedema caused by
LGV.25 This study also highlights that patients with LGV present
with a wide range of symptoms suggestive of other conditions
and are frequently coinfected with other STIs.7 8 26–29 Nearly
one-ﬁfth of LGV cases were coinfected with rectal gonorrhoea.
Most of the cases and controls were coinfected with HIV, in line
with other studies in the UK,4 and the one case of incident HIV
infection reinforces the recommendation for repeat HIV testing
and offer of other risk reduction interventions. Importantly,
rectal carcinoma should always be considered in those present-
ing with bleeding and weight loss; however, cases have been
reported where LGV has presented with an ulcerating bleeding
mass.28 29
The majority of patients with LGV were treated with the
recommended 3-week course of doxycycline.20 Due to the delay
in obtaining diagnostic conﬁrmation, treatment should be
started presumptively based on clinical symptoms along with
gonorrhoea treatment if clinically indicated. Patients conﬁrmed
with LGV should be offered a test of cure.
Generalisability
These ﬁndings from a multicentre study should be applicable in
areas where LGV has become established among MSM popula-
tions. The validity of the clinical predictors is highly dependent
on the prevalence of LGV and the proportion of cases that are
symptomatic and therefore the ﬁndings may not be applicable in
settings with a different epidemic pattern for LGV.
CONCLUSION
LGV is now an established infection among sexually active
MSM in the UK, particularly among those with HIV. Clinicians
should be aware that MSM presenting with any rectal symptoms
should be tested for LGV and treated presumptively, particularly
if they have one or more of tenesmus, constipation and exudate
on proctoscopy.
Key messages
▸ Tenesmus alone, or in combination with constipation, is
suggestive of lymphogranuloma venereum (LGV) in men
who have sex with men (MSM).
▸ If LGV is suspected, presumptive treatment with three weeks
of doxycycline should be given.
▸ LGV should be considered in the differential diagnosis of all
MSM presenting with rectal symptoms and tests for other
STIs should be carried out.
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